Want to join the conversation?
Janssen Pharmaceuticals, part of $JNJ, and its development partner Bayer HealthCare today declared results from PMSS and XANTUS. The results found the rates and patterns of major bleeding in routine clinical practice were low 2.89 and 2.1 per 100 person-years, respectively and generally consistent with those observed in Phase III clinical research.
$EXTR has been on an interesting uptrend, fundamentals kinda tricky but solid technical. Earnings 5th